

In the Claims:

1. (currently amended) A wound dressing for covering bleeding wounds, said wound dressing being a ready-made product and comprising a carrier material containing a compound selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline, wherein said compound is a vasoconstrictive medicinal substance, wherein the wound dressing is produced by a process comprising at least the steps of:

a) degassing a defined amount of a solvent or solvent mixture by using a light-impermeable vessel, or removing oxygen from a solvent or solvent mixture by using a light-impermeable vessel, or selecting and providing a solvent or solvent mixture which does not adversely affect the stability of a medicinal active substance that is instable in the presence of oxygen;

b) adding a defined amount of said vasoconstrictive medicinal substance;

c) dissolving the medicinal substance in the solvent or solvent mixture;

d) removing a partial amount of the solution and dripping the partial amount of the solution onto a carrier material;

e) drying and removing the solvent or solvent mixture; and

f) repeating steps d) and e), if required.

2. (previously presented) The wound dressing according to claim 1, wherein the carrier material contains at least one further vasoconstrictive medicinal substance selected from the group consisting of the sympathomimetics.

3. (previously presented) The wound dressing according to claim 1, wherein the carrier material further contains at least one substance selected from the group consisting of an astringent substance and a haemostatic substance.

4. (previously presented) The wound dressing according to claim 1, wherein the carrier material contains at least one further active substance for promoting wound healing but having no vasoconstrictive effect.

5. (previously presented) The wound dressing according to claim 4, wherein said at least one further active substance is selected from the group consisting of amino acids, peptides, enzymes, lymphokines, coagulation factors, anti-inflammatory substances, vitamins, polysaccharides and skin caring substances.

6. (previously presented) The wound dressing according to claim 1, wherein the carrier material is selected from the group consisting of wovens, interlaced yarns, crocheted fabrics, knit fabrics, nonwovens, papers, absorbent gauze, wadding, compresses, and combinations of said materials.

7. (previously presented ended) The wound dressing according to claim 6, wherein the carrier material has a low peroxide content.

8. (previously presented) The wound dressing according to claim 1, wherein the carrier material contains at least one additive selected from the group consisting of disinfectants, antioxidants, preservatives and moisture-absorbing substances.

9. (currently amended) ~~An adhesive~~ The wound dressing for covering bleeding wounds according to claim 1, wherein said wound dressing is an adhesive wound dressing comprising an active substance containing said carrier material containing a ~~compound selected from the group consisting of adrenaline and one of the~~

~~pharmaceutically acceptable salts of adrenaline~~ said medicinal substance, and further
comprising a backing layer connected with the carrier material, and a detachable
protective layer, the surface area of the backing layer being larger than the surface area of
the carrier material, and wherein an adhesive surface comprises the surface area of the
backing layer which projects beyond the surface area of the carrier material.

10. (previously presented) The adhesive wound dressing according to claim 9,
wherein said adhesive surface of the backing layer projects beyond the carrier material on
all sides to form an adhesive margin.

11. (previously presented) The adhesive wound dressing according to claim 9,
wherein said backing layer comprises a material selected from the group consisting of a
rigid material, a flexible material, an elastic material, and a composite material
comprising at least two of said rigid, flexible and elastic materials.

12. (previously presented) The adhesive wound dressing according to claim 9,
wherein a pressure-sensitive adhesive layer comprising a polymer matrix having at least
one additive forms one of said adhesive surface and said adhesive margin.

13. (previously presented) The adhesive wound dressing according to claim 12,
wherein the polymer matrix contains one of a pressure-sensitive adhesive base polymer
and a combination of at least two pressure-sensitive adhesive base polymers, the
polymer(s) being selected from the group consisting of natural rubber, synthetic rubber,
poly(meth)acrylic acid, poly(meth)acrylates, poly(meth)acrylate copolymers and
combinations of said polymers.

14. (previously presented) The adhesive wound dressing according to claim 12, wherein the polymer matrix contains at least one additive selected from the group consisting of plasticisers, tackifiers, stabilisers, carrier substances and fillers.

15. (previously presented) The adhesive wound dressing according to claim 9, wherein said adhesive wound dressing is singly packed in an oxygen-impervious packaging material and is protected against the action of light.

16. (currently amended) A process for producing a wound dressing ~~according to claim 1 or an adhesive wound dressing according to claim 9~~ for covering bleeding wounds, said wound dressing being a ready-made product and comprising a carrier material containing a compound selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline, wherein said compound is a vasoconstrictive medicinal substance, the process comprising at least the steps of:

- a) degassing a defined amount of a solvent or solvent mixture by using a light-impermeable vessel, or selecting and providing a solvent or solvent mixture which does not adversely affect the stability of a medicinal substance that is instable in the presence of oxygen;
- b) adding a defined amount of a vasoconstrictive medicinal substance selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline;
- c) dissolving the medicinal substance in the solvent or solvent mixture;
- d) removing a partial amount of the solution and dripping the partial amount of the solution onto a carrier material;
- e) drying and removing the solvent or solvent mixture; and

f) repeating steps d) and e), if required.

17. (previously presented) The process according to claim 16, further comprising the step of adding at least one further vasoconstrictive medicinal substance.

18. (currently amended) ~~[[The]]~~ A process according to claim 16 for producing an adhesive wound dressing for covering bleeding wounds, said wound dressing being a ready-made product and comprising a carrier material containing a compound selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline, wherein said compound is a vasoconstrictive medicinal substance, and further comprising a backing layer connected with the carrier material, and a detachable protective layer, wherein the surface area of the backing layer is larger than the surface area of the carrier material, and wherein the surface area of the backing layer is an adhesive surface which projects beyond the surface area of the carrier material, the process further comprising the steps of:

a) degassing a defined amount of a solvent or solvent mixture by mixture by using a light-impermeable vessel, or selecting and providing a solvent or solvent mixture which does not adversely affect the stability of a medicinal active substance that is instable in the presence of oxygen;

b) adding a defined amount of said vasoconstrictive medicinal substance;

c) dissolving the medicinal substance in the solvent or solvent mixture;

d) removing a partial amount of the solution and dripping the partial amount of the solution onto a carrier material;

- e) drying and removing the solvent or solvent mixture;
- f) repeating steps d) and e), if required;
- g) ~~Sticking~~ sticking the carrier material containing the medicinal substance to an adhesive surface of a backing layer; and
- h) covering the adhesive surface and the carrier material with a detachable protective layer.

19. (previously presented) A process for producing an adhesive wound dressing ~~according to claim 9~~ for covering bleeding wounds, said wound dressing being a ready-made product and comprising a carrier material containing a compound selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline, wherein said compound is a vasoconstrictive medicinal substance, and further comprising a backing layer connected with the carrier material, and a detachable protective layer, wherein the surface area of the backing layer is larger than the surface area of the carrier material, and wherein the surface area of the backing layer is an adhesive surface which projects beyond the surface area of the carrier material, further the process comprising the steps of:

- i) coating a surface of a backing layer with a pressure-sensitive adhesive layer, or providing a backing layer having a pressure-sensitive adhesive surface;
- ii) applying or sticking a carrier material to the adhesive surface of the backing layer;
- iii) preparing an active substance-containing solution by a) degassing a defined amount of a solvent or solvent mixture by using a light-impermeable vessel,

or selecting and providing a solvent or solvent mixture which does not adversely affect the stability of a medicinal substance that is instable in the presence of oxygen, b) adding a defined amount of a vasoconstrictive medicinal substance selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline and c) dissolving the medicinal substance in the solvent or solvent mixture and dripping said solution onto a carrier material to form an active substance-impregnated carrier material; and

iv) covering the active substance-impregnated carrier material and the adhesive surface of the backing layer with a detachable protective film.

20. (previously presented) The process according to claim 19, further comprising the steps of:

punching out individual surface pieces having a defined surface shape and surface size; and

packaging the individual surface pieces in one package per piece, the package comprising an oxygen-impervious and a light-impermeable packaging material.

21. (previously presented) The process according to claim 19, wherein the dripping step is carried out under exclusion of air.

22. (previously presented) The process according to claim 19, wherein the carrier material has a low peroxide content.

23. (currently amended) Use of a wound dressing according to claim 1 or an adhesive wound dressing according to claim [[19]] 9 for treating bleeding wounds, by administering adrenaline to bleeding wounds to stop the bleeding.

24. (canceled)

25. (previously presented) The wound dressing according to claim 5, wherein said amino acids are glycine.

26. (previously presented) The wound dressing according to claim 6, wherein the carrier material is selected from the group consisting of cotton fabrics, viscose fabrics, cotton-viscose blended fabrics, synthetic fibre wovens, synthetic fibre nonwovens, cotton wadding, viscose wadding, and gauze-wadding compresses.

27. (previously presented) The wound dressing according to claim 7, wherein the carrier material has a peroxide content not exceeding the value 10.

28. (previously presented) The adhesive wound dressing according to claim 11, wherein said material is selected from the group consisting of a metal foil and a plastic film.

29. (previously presented) The adhesive wound dressing according to claim 11, wherein said material is a metallised polymer film.

30. (previously presented) The adhesive wound dressing according to claim 29, wherein said metallised polymer film is a polymer film metallised with aluminium.

31. (previously presented) The wound dressing according to claim 1, wherein said wound dressing is singly packed in an oxygen-impervious packaging material and is protected against the action of light.

32. (previously presented) The process according to claim 21, wherein the dripping and drying is carried out under protective gas.

33. (previously presented) The process according to claim 16, wherein the dripping and drying steps are carried out under exclusion of air.

34. (previously presented) The process according to claim 33, wherein the dripping and drying steps are carried out under protective gas.

35. (previously presented) The process according to claim 22, wherein the carrier material has a peroxide number not exceeding the value 10.

36. (previously presented) The process according to claim 16, wherein the carrier material has a low peroxide content.

37. (previously presented) The process according to claim 36, wherein the carrier material has a peroxide number not exceeding the value 10.

38. (new) A wound dressing for covering bleeding wounds, said wound dressing being a ready-made product and comprising a carrier material containing a compound selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline, wherein said compound is a vasoconstrictive medicinal substance, wherein said carrier material is selected from the group consisting of wovens, interlaced yarns, crocheted fabrics, knit fabrics, nonwovens, papers, absorbent gauze, wadding, compresses and combinations of the materials, and wherein the carrier material has a low peroxide content.

39. (new) The wound dressing according to claim 38, wherein the carrier material has a peroxide content not exceeding the value 10.

40. (new) An adhesive wound dressing for covering bleeding wounds, said wound dressing being a ready-made product and comprising a carrier material containing a compound selected from the group consisting of adrenaline and one of the pharmaceutically acceptable salts of adrenaline, wherein said compound is a vasoconstrictive medicinal substance, and further comprising a backing layer connected with the carrier material, and a detachable protective layer, wherein the surface area of the backing layer is larger than the surface area of the carrier material, and wherein the surface area of the backing layer is an adhesive surface which projects beyond the surface area of the carrier material, and wherein the carrier material has a low peroxide content.
41. (new) The wound dressing according to claim 40, wherein the carrier material has a peroxide content not exceeding the value 10.
42. (new) The process according to claim 16, wherein said carrier material is selected from the group consisting of wovens, interlaced yarns, crocheted fabrics, knit fabrics, nonwovens, papers, absorbent gauze, wadding, compresses and combinations of the materials.
43. (new) The process according to claim 17, wherein said further vasoconstrictive medicinal substance is selected from the group consisting of the sympathomimetics.
44. (new) The process according to claim 18, wherein said carrier material is selected from the group consisting of wovens, interlaced yarns, crocheted fabrics, knit fabrics, nonwovens, papers, absorbent gauze, wadding, compresses and combinations of the materials.
45. (new) The process according to claim 19, wherein said carrier material is selected from the group consisting of wovens, interlaced yarns, crocheted fabrics, knit fabrics,

nonwovens, papers, absorbent gauze, wadding, compresses and combinations of the materials.

46. (new) The process according to claim 18, wherein said carrier material has a peroxide content not exceeding the value 10.

47. (new) The process according to claim 19, wherein said carrier material has a peroxide content not exceeding the value 10.